<DOC>
	<DOC>NCT00097617</DOC>
	<brief_summary>This study is a multicenter, open-label, observational, postmarketing surveillance study that will collect information on the use of Genentech growth hormone (GH) preparations to treat children with CRI in the United States.</brief_summary>
	<brief_title>A Study in Children With Growth Failure Due to Chronic Renal Insufficiency (CRI) or End Stage Renal Disease (ESRD)</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Failure to Thrive</mesh_term>
	<criteria>Children diagnosed with CRI or ESRD and treated with a Genentech GH preparation on or after 1 January 2001 CRI documented using the Schwartz formula indicates a calculated creatinine clearance (CrCl) of &lt;=75 mL/min/1.73 m^2 Ability to keep follow up appointments throughout the study Subjects receiving a nonGenentech GH preparation Subjects with closed epiphyses Subjects with active neoplasia Current participation in another GH clinical study Current participation in the core study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>